Medicare GLP 1 changes for 2027 pair a $50 Bridge copay with a $274 semaglutide price
Medicare's 2027 booklet lists a $50 monthly GLP 1 Bridge copay for some Part D enrollees, and CMS has set a $274 negotiated price for Ozempic, Rybelsus and Wegovy from January 1. Neither number is what every patient will pay.
Who feels it
-
Patients
Rethink
Eligible Part D enrollees may pay $50 a month through the Bridge, and semaglutide gets a $274 negotiated price from January 1, 2027.
-
Prescribers
Adjust
Patients will ask whether a GLP 1 drug fits and whether they meet Bridge rules before December 7.
-
Pharmacies
Adjust
Drugmakers must make the negotiated price available to pharmacies that dispense semaglutide from January 1, 2027.
-
Payers
Adjust
Part D plans must list drugs with negotiated prices, while each plan still sets its own cost sharing.
-
Sellers
Worth knowing
A $50 Medicare route may draw some older cash or compounded GLP 1 users who qualify.
The Medicare GLP 1 changes for 2027 come down to two numbers: a $50 monthly copay through a new weight loss program and a $274 negotiated price for semaglutide. Both arrive while people on Medicare pick next year's coverage, and open enrollment closes on December 7. The details come from the federal government's 2027 Medicare booklet, which AOL summarized for readers on November 6. Neither number promises what a given patient will pay, and each one carries its own fine print.
What changes for GLP 1 drugs in 2027
The Centers for Medicare & Medicaid Services set out next year's changes in a booklet called "Your Medicare in 2027: What's New & Changing," published in September 2026. A consumer guide on AOL drew on that booklet to list the changes most likely to touch household budgets. Two of the Medicare GLP 1 changes stand out. The first is the Medicare GLP 1 Bridge, a program that offers a flat copay to some people who want help losing weight. The second is the next round of Medicare drug price negotiation, which puts Ozempic, Rybelsus and Wegovy on a list of 15 brand name medicines with new prices from January 1, 2027. Other items in the booklet, such as telehealth and online diabetes prevention classes, touch drug costs less directly.
The negotiated list also includes two type 2 diabetes tablets, Tradjenta and Janumet, along with drugs for cancer, lung disease, psoriasis and mental health. For readers of this site, the semaglutide group matters most, because it covers one molecule sold as a diabetes injection, a diabetes tablet and a weight loss injection. The table below sets out what is confirmed and when it starts. It draws only on the federal booklet, as reported by AOL, and on the CMS fact sheet that lists the 2027 negotiated prices. Plan premiums, deductibles and drug tiers for 2027 are not listed, because each Part D insurer sets its own and they differ from one plan to the next.
| Item | What it is | When | Who it reaches |
|---|---|---|---|
| Open enrollment | Last day to choose 2027 coverage | December 7, 2026 | Everyone picking a Medicare plan |
| GLP 1 Bridge | $50 copay for a one month supply | Listed for 2027 | Part D enrollees whose plan does not already pay and who meet other rules |
| Semaglutide negotiated price | $274 maximum fair price for a 30 day supply, against a $959 list price in 2024 | January 1, 2027 | Part D enrollees using Ozempic, Rybelsus or Wegovy |
| Second negotiation round | 15 brand name medicines | January 1, 2027 | Part D enrollees using any of the 15 |
How the Medicare GLP 1 Bridge works
According to the CMS booklet as summarized by AOL, the Medicare GLP 1 Bridge is aimed at people on Medicare who want help losing weight and whose drug plan does not already pay for a GLP 1 medicine. Enrollees need Part D drug coverage to take part. If they qualify, they pay a $50 copay for a one month supply. The booklet also says other eligibility rules apply, so not everyone who asks will get in. Those rules are not spelled out in the AOL piece, which sends readers to the Medicare.gov page for the program. Our earlier report on who qualifies for the Bridge walks through the criteria that Medicare has described so far, including the diagnosis rules.
The $50 figure is a fixed copay for people who qualify, while the $274 semaglutide figure is a negotiated program price and not a copay.
The practical catch is the order of steps. A patient first needs a prescriber who agrees that a GLP 1 drug fits, then a Part D plan in place for 2027, then a check against the Bridge rules. The AOL guide advises readers to talk with a doctor first and to secure drug coverage during open enrollment. It does not say which brands the Bridge covers, how claims are processed or when the program ends, so those points need checking on Medicare.gov. The $50 figure is a fixed copay for people who qualify, while the $274 semaglutide figure is a negotiated program price and not a copay. Mixing up the two numbers is the easiest mistake to make this fall.
What the Ozempic negotiated price means at the counter
Semaglutide was one of 15 Part D drugs that CMS picked for its second cycle of price talks. The agency's fact sheet on negotiated prices lists $274 as the agreed price for a 30 day supply of Ozempic, Rybelsus and Wegovy in 2027, against a 2024 list price of $959, a 71 percent discount. CMS says about 2.28 million Part D enrollees used these semaglutide drugs in 2024. The price applies across dosage forms and strengths, so the amount per package differs by product. By law, standalone Part D plans and Medicare Advantage drug plans must include the selected drugs on their formularies. Being on a formulary is not the same as having a low copay, though.
The Ozempic negotiated price sets what the drug can cost inside the program, and CMS says drugmakers must make it available to eligible people and to the pharmacies that dispense the drug. What an enrollee pays at the counter still depends on the plan's deductible, its drug tiers and whether it charges a flat copay or a share of the price. CMS estimates that Part D enrollees would save about $685 million in out of pocket costs across all 15 drugs under the standard benefit design, a total that says nothing about any one person's bill. Wegovy Medicare coverage through a regular plan and the Bridge are separate routes. The AOL guide also tells readers to compare coupon prices with their plan's price before filling.
Part D open enrollment choices before December 7
Open enrollment for 2027 coverage closes on December 7, and the AOL guide stresses that the coverage choice decides which perks a person can use. The Bridge requires Part D. A separate program called ACCESS, which links doctors with outside groups that help people manage chronic conditions such as diabetes at home, is limited to Original Medicare. Anyone weighing a Medicare Advantage plan against Original Medicare with a standalone drug plan should check both points before signing up. During Part D open enrollment, the guide suggests looking up each prescription on the negotiated drug list. Plan comparisons are available through Medicare.gov/plan-compare, the federal tool named in the booklet, and the same site lists which doctors accept Medicare.
Several points remain unclear from the published material. The guide gives no 2027 copays for Ozempic, Rybelsus or Wegovy under any named plan, and the $274 figure is a program price rather than a national copay. Nothing in it says how many people will qualify for the Bridge or how long the program will run. People who have been paying cash or using compounded copies may look at a $50 copay with interest, but it applies only to those who meet the rules and hold Part D cover. Anyone unsure about Medicare eligibility itself can call 1-800-MEDICARE or Social Security, the booklet says. Our coverage beat will follow the Medicare GLP 1 changes as plans publish their 2027 terms.
Conclusion
The Medicare GLP 1 changes for 2027 give eligible people two routes to lower costs: a $50 Bridge copay for weight loss and a $274 negotiated price for the semaglutide group from January 1. Neither is automatic. The Bridge needs Part D and set eligibility rules, and the negotiated price passes through each plan's own cost sharing. People who want either should confirm drug coverage before open enrollment ends on December 7 and check details on Medicare.gov. This story is for information only and is not medical or insurance advice.
Source CMS booklet Your Medicare in 2027: What's New & Changing (September 2026), as reported by AOL on November 6, 2026; CMS fact sheet on negotiated prices for 2027
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.